A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany
Abstract Background: A total of 62/66 (93.9%) residents in a senior citizen home in Bremen, Germany, received the first dose of the Biontech/Pfizer vaccine BNT162b2 on December 27th 2020. After routine severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antigen tests showed positive results...
Main Authors: | Rolf Schwarzer, Sabine D. Freys, Nick Neuwinger, Nina Beikert, Bettina Eberspächer, Anke Edelmann, Marta Zuchowski, Inga Slothouwer, Angela Stein, Kathrin Theil, Peter Menzel, Jörg Hofmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-12-01
|
Series: | Immunity, Inflammation and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1002/iid3.532 |
Similar Items
-
A racing heart post‐Pfizer/BioNTech BNT162b2
by: Hooi Khee Teo, et al.
Published: (2022-10-01) -
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021-12-01) -
Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome
by: Mohammad Altermanini, et al.
Published: (2023-08-01) -
Bibliometric Analysis of Pfizer-BioNTech (BNT162B2): A COVID-19 Vaccine
by: Waseem Hassan, et al.
Published: (2021-09-01) -
Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
by: Akihiro Matsubara, et al.
Published: (2021-12-01)